...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: SF

The company has a credibility problem vis-a-vis general investors.  IMO, most will only skim when doing DD.  What do the masses see?  20 Years of zigging and zagging through many failed trials including the most recent and critical Phase 3.  Sure, the company received a FDA BTD, but Joe Retail won't take the time to assess its value, especially since there is an entire trial yet to be set-up, run, completed and then eventually reported on.  Then waiting for an NDA and approval.  Joe Retail will look backwards and check the SP reaction to BTD news and see the zero reaction to the SP, and then looking forward Joe Retail sees YEARS of waiting to prove up this "nebulous" and complex new science.  Its a non-starter for the vast majority of investors, imo.

Joe Retail will however react to a CEO's tone when speaking of the promise of a lead drug.  Don is no Anthony Robins, much less a Steve Ballmer.  Don't you think people would draw on a little more excitement?   We're talking about saving millions of lives aren't we?  Making billions in revenue, right? Can't we get Don to show a little more enthusiasm?

Share
New Message
Please login to post a reply